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Summary. Although several immunologic parameters have 
been found to be abnormal, their precise relationship to the 
cause of the disease remains unclear. It is believed that a 
virus initiating a bout of myocarditis may play a role in the 
perpetuation of the chronic phase, probably via immuno- 
logic mediation. A selection acquired defect or damage to a 
subpopulation of suppressor T lymphocytes is possible, pro- 
viding the basis for the development of an autoimmune 
disorder. Studies in mice have shown a clear link between 
active viral myocarditis and the subsequent development of 
cardiomyopathy. However, the trigger mechanism that 
initiates the cardiomyopathy is still elusive. Specific anti- 
gens, possibly altered virus or damaged cardiac tissue, may 
be playing the role of the "hidden or cloistered" antigen in 
eliciting the immunologic reactions through a cytotoxic T- 
celt mechanism. Identification and isolation of the specific 
"antigen" in question could,resolve the dilemmas about the 
immunopathogenesis of cardiomyopathy in humans. 
The purpose of this communication is to review and 
examine the rote of immunologic factors in dilated cardio- 
myopathy (DCM) in man. In this review we will focus on the 
role of (1) heart reactive antibodies, (2) cell-mediated im- 
munity, and adduce (3) relevant data from experimental 
models of myocarditis that have bearing on the mechanisms 
involved in acute myocarditis; we will speculate on the 
possible link to subsequent development of dilated 
cardiomyopathy. 
Possible virus etiology in dilated eardiomyopathy 
Despite continuing present and past efforts, the etiology of 
dilated cardiomyopathy remains elusive. A nonspecific 
upper respiratory illness not infrequently heralds the onset 
of severe cardiac symptoms. In this setting, increased neu- 
tralizing antibody titers against Coxsackie B, echo and 
herpes virus have been noted by Sinani et al. [1] as well as by 
Kawai and Takutsu, [2]. Patients with other forms of heart 
disease did not show similar elevation in viral titers. Cam- 
bridge et al. have noted significantly higher viral titers in 
DCM, particularly in those with illness for less than I year, 
compared with age- and sex-matched patients with other 
forms of heart disease [3]. As additional support for the viral 
etiology, Kawai reported the presence of viral antigens in 
biopsy specimens of myocardium from a patient with DCM 
[4]. It is well recognized that only a few patients with infec- 
tions due to the ubiquitous virus developed the character- 
istic syndrome alluded to above. Although genetic predispo- 
sition has not been systematically studied, Cambridge et al. 
found that HLA distribution frequencies in 20 of their pa- 
tients with DCM were no different from those observed in 
the general population [3]. Not all patients with clinical 
myocarditis necessarily developed features of dilated 
cardiomyopathy at long-term follow-up [5]. Although the 
initial symptoms and signs in myocarditis may be attributed 
to viral invasion of the myocardium, the subsequent course 
of the disease, namely the chronic indolent form clinically 
recognized as dilated cardiomyopathy, is not thought to be 
due to persistence of viral effects on the myocardium [I]. At 
this chronic stage, an immune mediation is suspected, pos- 
sibly triggered initially by the virus or perhaps by new anti- 
gens formed from necrotic myocardium and perpetuated via 
an autoimmune process [6]. Clinical support for incrimina- 
tion of an immunologic mediation in DCM include: (1) the 
observation that cardiac symptoms follow an upper respi- 
ratory infection in previously healthy individuals, (2) a clin- 
ical course punctuated by recurrences of heart failure with- 
out obvious cause, (3) occasional clinical response to anti- 
inflammatory drugs, (4) the demonstration of heart reactive 
antibiodies in some patients along with other serologic ab- 
normalities, including hypergammaglobulinemia, antinu- 
clear antibodies, rheumatoid factors, and biologic false- 
positive serologic tests for syphilis, (5) demonstration of 
abnormality in cell-mediated immunity in various propor- 
tions of these patients, and (6) the not infrequent findings 
of lymphocytic and mononuclear infiltrates in the myo- 
cardium of these patients. 
Heart reactive antibodies 
The prevalence of heart reactive antibodies (HRA) in DCM 
has varied from 17% to 40%. Because of their relative low 
prevalence and occurrence in other forms of heart disease, 
sometimes in higher frequency than in cardiomyopathy, 
doubt has been cast on whether these antibodies have any 
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pathogenic role in the disease [7]. However, Bolte and Schul- 
theiss showed that presence of HRA correlated with severity 
of symptoms and duration of the disease [8]. Previously we 
had observed that patients who were significantly disabled 
(class IV, New Heart Association) and who underwent car- 
diac transplantation had no circulating HRA prior to their 
transplant operation [9]. Despite the absence of  l iRA in the 
serum, cardiac tissue from these individuals showed exten- 
sive deposits of bound gammaglobulin and complement. It 
was postulated from this observation that the heart in ad- 
vanced cardiomyopathy may preferentially fix heart reac- 
tive immunoglobulins to specific sarcolemmal and subsar- 
colemmal antigens, and consequently HRA may disappear 
from the serum. It was also surmised that binding of HRA 
may result in decreased ventricular function, either directly 
or indirectly via an inflammatory process. In a later study, 
Bolte, et al. correlated lgG binding to myocardial tissue with 
ejection fraction in patients with DCM [10]. Approximately 
75% of patients with an ejection fraction of less than 35% 
showed lgG binding to myocardial tissue compared with 
approximately 45% of  a second group of  patients with 
DCM whose ejection fraction was greater than 35%. In a 
miscellaneous group with cardiomyopathy due to various 
causes, including coronary artery disease and an ejection 
fraction greater than 50%, lgG binding was found in only 
25% of the patients. This study did not, however, evaluate 
similar patients with low ejection fraction. There is doubt as 
to the role HRA may play in the chronic phase of the disease 
as they are felt to be the result of injury regardless of  the 
nature of the injury. However, in a limited study, Bengmark 
et al. showed that sera of  patients with myocarditis, includ- 
ing two with idiopathic pericarditis, had cytotoxic effects on 
cardiac explants of newborn rat heart cells [11]. Technical 
difficulties, including the problems of obtaining and cultur- 
ing adult heart cells and using them as target cells in 
cytotoxic experiments,thwarted extensive investigations of 
this type. Using newer techniques in cell preparation, 
Maisch et al. have shown that antisarcolemmal antibiodies, 
via antibody-dependent cytotoxicity, may play a role in the 
pathogenesis of human myocarditis [12]. In a very important 
follow-up study, these authors showed that all patients with 
DCM with prior evidence of myocarditis had antimyolemmal 
antibodies, which induce cytolysis of  vital cardiocytes [13]. 
Furthermore, the titers of antibody correlated with the 
degree of cardiocytolysis. Thus, in the light of these studies, 
the whole issue about the role of HRA in myocarditis and 
DCM may have to be re-examined. 
Cell-mediated immunity in DCM 
Concurrent with the demonstration of HRA and DCM, 
simultaneous studies of cell-mediated immunity (CMI) 
were carried out. In our earlier study, CMI was evaluated 
by studying phytohemagglutinin (PHA) and human heart 
extract induced lymphocyte transformation [14]. Lympho- 
cytes from 14 patients with cardiomyopathy, 17 with other 
forms of  heart disease (five ischemic, eight rheumatic, three 
congenital, and one myocarditis), and 22 normal subjects 
were investigated. Transformation was expressed as a ratio 
of counts of tritiated thymidine uptake by lymphocytes 
stimulated by PHA or heart extract to unstimulated lym- 
phocytes (S/u ratio). An S/u ratio equal to or greater than 50 
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indicated intact or normal CMI to mitogen, while an S/u 
ratio less than 10 indicated markedly depressed CMI. With 
heart extract, an S/u ratio of  less than 2 was normal, while 
one greater than 2 was considered abnormal, consistent with 
prior sensitization of  the lymphocytes. The S/u ratio with 
PHA for the cardiomyopathy group was 83 _+ 26 (mean 
+ SEM), for the heart disease group 93 _+ 17, and for the 
normal control individuals 262 _+ 3 I. The differences ob- 
served in the S/u ratios between the normal and cardiomy- 
opathy groups and between the normal and heart disease 
groups was significant (P < 0.01). A bimodal distribution of 
S/u ratios was evident among the cardiomyopathy patients. 
Six in this group had an S/u ratio with PHA of less than 10, 
indicating severely depressed CMI, whereas no patients in 
the disease control group or in the normal group had S/u 
ratios this low. Clinical features, such as age, sex, duration 
and severity of disease, drugs used, and results of standard 
delayed hypersensitivity skin tests, were not different among 
the cardiomyopathy patients with low or normal PHA re- 
sponses. Crossover studies using AB + in place of  autolog- 
ous serum resulted in a significant return toward normal in 
the PHA responses in these patients. Of interest is the ob- 
servation that sera of  three of  the six patients prevented 
normal peripheral blood lymphocytes from responding to 
PHA. All three of these patients died from their disease soon 
afterward. 
Lymphocyte responses to heart muscle showed that the 
S/u ratio for the cardiomyopathy group was 1.9 4- 0.5, for 
the heart disease group 2.3 _+ 1, and for the normal group 
1.2 _+ 0.1. The differences between each of these groups 
were not significant. An S/u ratio greater than 2 consistent 
with prior cardiac sensitization to heart muscle was seen in 
four patients with cardiomyopathy as well as in two with 
heart disease, both with rheumatic etiology, and one normal 
subject. This study suggests that cardiomyopathy does not 
represent a homogenous disorder from an immunologic 
standpoint as approximately 30%-40% of  the patients 
showed evidence of abnormal CMI. Sachs and Lanfranchi 
showed reduced lymphocyte stimulation to PHA as well as 
absolute reduction in the percentage of circulating T lym- 
phocytes in a high proportion of  their patients with cardio- 
myopathy [15]. Using the leukocyte migration inhibition 
test (LMI), another in vitro correlate of  CMI, we investigated 
12 patients with cardiomyopathy, 27 patients with ischemic 
heart disease (IHD), and 19 normal subjects [16]. Con- 
conavalin A (Con A) and human heart muscle extract as 
antigen were used in the two-stage LMI assay. Although the 
mean LMI responses to Con A were not significantly differ- 
ent in the three groups, a distinct bimodal response above 
and below a 90% confidence limit was noted in the DCM 
group. Five of twenty-seven patients with IHD (19%), 2 of 
19 normal subjects (11%), and 5 of 12 patients with DCM 
(42%) had abnormal responses to Con A (above the 90% 
confidence limit). The proportion of patients with abnormal 
Con A responses was significantly higher in the DCM group 
than in the normal group (P < 0.05). Although LMI to 
heart extract was noted in 3 of  12 patients with DCM (25%), 
14 of  27 patients with IHD (52%), and 2 of 19 (10%) of  the 
control group, there was a significant difference in the mean 
LMI response to heart extract only between the IHD group 
and the control group (P < 0.05). Again, this study, similar 
to the results from lymphocyte transformation cited earlier, 
indicated that only 40% of these patients may show dis- 
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turbances of CMI. However, Moulias et at. found a higher 
proportion of their patients with DCM that exhibited ab- 
normal LMI to myocardial extract [17]. 
In another type of study, Jacobs et al. studied CMI in a 
variety of heart diseases in order to assess its role in DCM 
[18]. They found that lymphocytes from 23 of 73 patients 
with DCM (30%), 36 of 148 patients with other forms of 
heart disease (24%), mainly rheumatic and ischemic, and 2 
of 49 normal subjects (4.9 %) showed evidence of cytotoxic- 
ity to cultured human heart cells. These authors concluded 
that lymphocyte cytotoxicity to heart muscle was not spe- 
cific for DCM but may also occur following myocardial 
damage due to a variety of causes. Despite the technical 
limitations in performing this study, it represents an impor- 
tant attempt at elucidating the pathogenic mechanisms in 
DCM. Anderson et al. suggested another possible immune 
mechanism in DCM [19]. They noted that 6 of 37 patients 
with DCM who were under the age of 40 years and who had 
received cardiac transplants because of severe heart failure 
developed lymphoma, while 0 of 54 patients with coronary 
artery disease who received similar allografts developed 
malignancy. Serum from one of the patients with lymphoma 
inhibited normal suppressor cell function, while sera from 
the other five were not tested. Normally, suppressor T cells 
prevent excessive lymphoid proliferation as a result of anti- 
genic stimulation. I t  was postulated that in circumstances 
where suppressor T-cell function was defective, antigenic 
stimulation to alloantigens may lead to abnormal lymphoid 
proliferation, sometimes resulting in lymphoma. Following 
up on this observation, Fowles et al. demonstrated defec- 
tive T-suppressor cell function in DCM but not in coronary 
artery disease [20]. Eckstein et al. have shown similar de- 
creased suppressor T-cell activity in patients with DCM and 
myocarditis [21]. However, in another study by Anderson 
et at. generalized defective suppressor T-cell function was 
not confirmed [22]. Recently, defective natural killer cell 
activity has also been shown in about 50% of patients with 
DCM, raising an important question as to the pathogenesis 
of DCM [23]. Natural killer cells with non-T and non-B 
characteristics are known to provide early defense against 
invading virus infection. Defective killer cell activity could 
thus allow for the insidious propagation of the inflamma- 
tory process. The above authors also noted that HLA-A3 
tissue type was associated with defective natural killer ac- 
tivity in their patients. Many immunologic processes are 
governed by a variety of cell-cell mechanisms regulated by 
the T-helper cells as well as by T-suppressor cells. Waldmann 
et al. have reviewed theories on the pathogenesis of immune 
deficiency and autoimmune diseases related to abnormal 
suppressor mechanisms [24]. Significant suppressor cell 
dysfunction has been elucidated as an important underlying 
mechanism in autoimmune diseases, such as systemic lupus 
erythematoses [25]. If suppressor cell function is indeed 
defective, future research may profitably be focused on 
investigating factors affecting its role, i.e,, serum factors, 
acquired or inherited abnormalities, or destruction of these 
specific subsets of T cells. 
Experimental myocarditis 
Recent studies of experimental myocarditis have led to an 
important understanding in the pathogenesis ofmyocarditis 
and possibly in human DCM. In an important study, Wil- 
son et al. showed that Coxsackie B virus-induced infection 
in mice resulted in active myocarditis, associated with viral 
replication in myocytes and recovery of virus from the myo- 
cardium for periods up to 1 week [26]. This phase was 
followed by a period of chronic indolent myoearditis during 
which virus was not recoverable. The histologic changes 
during this phase were not dissimilar to those encountered 
in human cardiomyopathy. An immune mechanism was 
thought likely as a possible cause for these late changes. In 
another important study, Matsumori and Kawai, for the 
first time, produced in experimental mice injected with en- 
cephalomyocarditis virus typical histologic features, along 
with cardiac dilatation, seen in human DCM long after the 
acute phase of myocarditis has resolved [27]. These changes 
were associated with increased mortality ascribed to conges- 
tive heart failure. Woodruff and Woodruff in their pioneer- 
ing studies using Coxsackie-infected mice showed that prior 
T-cell deprivation led to significant reduction in the severity 
of the myocarditis and subsequent mortality [28]. Wong et 
al. from the same laboratory showed that infected animals 
could mount ceil-mediated immune responses with the 
production of specific T cells, having cytotoxic properties 
directed particularly against in vitro infected cells [29]. How- 
ever, these activated T cells, if recovered from the spleen, did 
not show similar cytotoxieity against uninfected myocytes. 
Subsequently, Huber et al. confirmed the presence of T- 
cytotoxic cells recovered from the spleen 5 days after the 
infection [30]. Furthermore, these authors showed that pre- 
treatment of cytotoxic ceils with antilymphocyte serum 
(anti-THY 1,2) and complement prevented lysing of the 
target cells. However, incubation with immune serum and 
complement did not abolish or reduce the cytotoxic poten- 
tial of  the cells. Maximal cytotoxicity occurred against 
infected syngeneic myofibers, as opposed to allogeneic 
myocytes, providing evidence that virus-specific effector cells 
were T lymphocytes. These authors in a study showed that 
splenic cells which were recovered early (3 days after viral 
innoculation) could also cause lysis of uninfected myocytes 
[31]. The effector cells killed a wide range of target ceils, 
including myocytes, endothelial cells, and fibroblasts. Their 
cytotoxicity was not inhibited by either anti-lg or anti-THY 
1,2 antisera, unlike cytotoxic T cells recovered late (5 days 
after infection). It was postulated that the early effector cells 
might represent a population of natural killer cells. In this 
study, these authors, having noted previously that female 
mice infected with Coxsackie B3 virus developed a milder 
degree of inflammatory myocarditis and subsequent lower 
mortality than males, showed that infected female mice 
did not produce appreciable numbers of T-cytotoxic cells 
compared with the males. Female mice produced almost 
exclusively natural killer cell populations, which were 
less cytopathic than the other immune T-cytotoxic cells. 
Castration of the male mice prior to viral infection resulted 
in reduced mortality, myocardial inflammatory responses, 
and the development of T-cytotoxic tymphocytes [32]. 
Thus, in the course of experimental myocarditis, at least 
two sets of effector cell populations appear. The earlier set 
observed usually within 3 days of infection probably rep- 
resents natural killer cells. These cells have nonspecific 
cytotoxic properties against a wide range of target cells. It is 
possible that these killer ceils might serve to clear or contain 
the primary infection. The second set of effector cells with 
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character is t ics  o f  T cells is observed later,  usual ly  5 days  
af ter  infection,  and  they have specific effects d i rected toward  
the virus-infected or  damaged  myocytes  with lysis o f  syn- 
geneic target  cells. I t  is envisioned tha t  these T-cyto toxic  or  
au to immune  cells might  be par t ia l ly  responsible  for  the 
acute and possibly the chronic in f lammatory  changes ob- 
served in these models.  Fur the r  studies with respect  to the 
mechanism of  the chronic changes in the myoca rd ium lead- 
ing to the stage o f  di lated c a r d i o m y o p a t h y  are  eagerly 
awaited.  
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Discussion 
Discussants: Das,  Maisch,  Spry,  A m o r i m ,  K i t a u r a  
It  was concluded that  there is evidence for an immuno-  
suppressive fac tor  or  factors  in d i la ted  c a r d i o m y o p a t h y  
and that  there is some exper imental  evidence of  damage  to 
myof ibers  caused by sensitized lymphocytes .  
